• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>British journal of ophthalmology >Subretinal coapplication of recombinant tissue plasminogen activator and bevacizumab for neovascular age-related macular degeneration with submacular haemorrhage.
【24h】

Subretinal coapplication of recombinant tissue plasminogen activator and bevacizumab for neovascular age-related macular degeneration with submacular haemorrhage.

机译：视网膜下联合应用重组组织纤溶酶原激活剂和贝伐单抗用于新血管性年龄相关性黄斑变性伴黄斑下出血。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

AIM: To evaluate the efficacy and safety of pars plana vitrectomy (ppV) with subretinal coapplication of recombinant tissue plasminogen activator (rtPA) and bevacizumab, and fluid-gas exchange for neovascular age-related macular degeneration (AMD) with submacular haemorrhage (SMH). METHODS: Consecutive interventional case series of 12 patients with neovascular AMD with SMH with a maximum history of 14 days. All patients underwent ppV with subretinal coapplication of rtPA and bevacizumab, and fluid-gas (20% SF6) exchange. Phakic patients underwent concomitant cataract surgery. Additional injections of bevacizumab were applied intravitreally 4 and 8 weeks postop. RESULTS: Complete displacement of SMH from the fovea was achieved in 9 of 12 patients. The mean best-corrected visual acuity (BCVA) improved significantly from preop logMAR 1.9 (range 3.0 to 0.7) to logMAR 1.2 (range 3.0 to 0.3) at 4 weeks postop (p = 0.01) and to logMAR 0.9 (range 1.6 to 0.2) at 12 weeks postop (p = 0.006). The mean improvement of BCVA 4 weeks postop as compared with preop was logMAR 0.7 (range -0.2 to 2.3). The mean improvement of BCVA 12 weeks postop as compared with preop was logMAR 0.96 (range -0.3 to 2.8). Overall, at 12 weeks postop, BCVA had improved in 10 patients, remained unchanged in one patient and worsened in one patient. CONCLUSION: PpV with subretinal coapplication of rtPA and bevacizumab, and fluid-gas exchange effectively displaces SMH and improves visual acuity in most patients.
机译：目的：通过视网膜下联合应用重组组织纤溶酶原激活物（rtPA）和贝伐单抗，以及进行液-气交换治疗新生血管性年龄相关性黄斑变性（AMD）和黄斑下出血（SMH），来评估平板玻璃体切除术（ppV）的有效性和安全性。方法：连续性介入治疗的12例新血管性AMD合并SMH患者的病史，最长病史为14天。所有患者均接受rtV和贝伐单抗视网膜下联合应用ppV，并进行液-气（20％SF6）交换。有眼症的患者要接受白内障手术。术后4周和8周玻璃体内再次注射贝伐单抗。结果：12例患者中有9例从中央凹完全置换SMH。术后4周（p = 0.01），平均最佳矫正视力（BCVA）从术前logMAR 1.9（范围3.0至0.7）显着提高至logMAR 1.2（范围3.0至0.3）（p = 0.01）和logMAR 0.9（范围1.6至0.2）术后12周（p = 0.006）。与术前相比，术后4周BCVA的平均改善为logMAR 0.7（范围-0.2至2.3）。与术前相比，术后12周BCVA的平均改善为logMAR 0.96（范围-0.3至2.8）。总体而言，术后12周，BCVA改善了10例，1例保持不变，1例恶化。结论：rtPA和贝伐单抗联合视网膜下联合应用PpV和液-气交换可有效替代大多数患者的SMH并提高视力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号